Author

Hana Nůsková

German Cancer Research CenterORCID 0000-0002-5562-9207Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:proteomics· 2 Research Focus:benchmarking· 1 Research Focus:perturbation response prediction· 1 Approach:wet-lab / biochemical assay· 1

Frequent Co-Authors

Aubry K. MilleriD· 3 shared Frank H. DeisiD· 2 shared Jana SamariniD· 2 shared Nikolas GunkeliD· 2 shared Annette Kopp‐SchneideriD· 1 shared Aurelio A. TelemaniD· 1 shared Bozhidar S. IvanoviD· 1 shared Britta BrüggeriD· 1 shared

Activity by Year

2023-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Aubry K. MillerORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Disrupting linearity of PROTAC scaffolds prevents off-target complex I inhibition

Nick Richert, Hana Nůsková, Jana Samarin, Bozhidar S. Ivanov, Mohamad Saoud, Frank H. Deis, Nicole de Vries, Sonja Sievers, Gernot Poschet, Slava Ziegler, Judy Hirst, Nikolas Gunkel, Aubry K. Miller

The paper identifies that linear PROTAC scaffolds inhibit mitochondrial complex I, leading to ATP depletion, and proposes structural modifications to mitigate this off-target effect.

bioRxiv · Apr 24, 2026 · PreprintCancer Biology

Differential KEAP1/NRF2 mediated signaling widens the therapeutic window of redox-targeting drugs in SCLC therapy

Jana Samarin, Hana Nůsková, Piotr Fabrowski, Mona Malz, Eberhard Amtmann, Minerva Taubert, Daniel Pastor‐Flores, Daniel N. Kazdal, Roman Kurilov, Nicole de Vries, Hannelore Pink, Frank H. Deis, Johanna Hummel-Eisenbeiss, Lisa Renz, Kamini Kaushal, , Nikolas Gunkel

The paper shows that activating the NRF2 pathway can safely increase the dose of TXNRD1 inhibitors in SCLC treatment without harming healthy tissues.

Nature Communications · Apr 11, 2026Peer-reviewedCancer Biology

Competition for cysteine acylation by C16:0 and C18:0 derived lipids is a global phenomenon in the proteome

Hana Nůsková, Fabiola Garcia Cortizo, Lena Sophie Schwenker, Timo Sachsenheimer, Egor E. Diakonov, Marcel Tiebe, Martin Schneider, Jasmin Lohbeck, Carissa Reid, Annette Kopp‐Schneider, Dominic Helm, Britta Brügger, Aubry K. Miller, Aurelio A. Teleman

The paper identifies 218 C16:0-acylated and 308 C18-lipid-acylated proteins, showing widespread competition for acylation across the proteome.

Journal of Biological Chemistry · Jul 24, 2023Peer-reviewedMolecular Biology